Ergoteles LLC Alaunos Therapeutics, Inc. Transaction History

Ergoteles LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.5 - $261.0 $185,651 - $96.9 Million	-371,303 Reduced 76.49%	114,131 $74,000
Q3 2022 Nov 14, 2022	SELL	$1.04 - $322.5 $469,524 - $146 Million	-451,466 Reduced 48.19%	485,434 $835,000
Q2 2022 Aug 12, 2022	BUY	$0.41 - $1.24 $384,129 - $1.16 Million	936,900 New	936,900 $1.16 Million
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.89 $233,260 - $404,460	-214,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1.44 - $2.73 $242,208 - $459,186	168,200 Added 367.25%	214,000 $389,000
Q2 2021 Aug 12, 2021	BUY	$2.63 - $3.67 $120,454 - $168,086	45,800 New	45,800 $121,000
Q4 2020 Feb 11, 2021	SELL	$2.09 - $3.09 $35,948 - $53,148	-17,200 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$2.39 - $3.43 $41,108 - $58,996	17,200 New	17,200 $43,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.